In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


This content is currently on FREE ACCESS, enjoy another 54 days of free consultation

In these unprecedented times, the ESC is doing everything it can to support its community: FREE access to all ESC 365 content until 31 July: explore more than 125,000 educational resources.

From 1 August onwards, support our mission by becoming a member.

Decrease in heart rate have more impact than up-titration of beta blocker for acute decompensated heart failure with atrial fibrillation

Session Poster Session 3

Speaker Takashi Morinaga

Event : Heart Failure 2019

  • Topic : heart failure
  • Sub-topic : Acute Heart Failure: Pharmacotherapy
  • Session type : Poster Session

Authors : T Morinaga (Kokura,JP), A Isotani (Kokura,JP), S Fujioka (Kokura,JP), K Hirose (Kokura,JP), S Mori (Kokura,JP), K Ishizu (Kokura,JP), S Ito (Kokura,JP), M Yano (Kokura,JP), M Fukunaga (Kokura,JP), S Shirai (Kokura,JP), K Ando (Kokura,JP)

Authors:
T Morinaga1 , A Isotani1 , S Fujioka1 , K Hirose1 , S Mori1 , K Ishizu1 , S Ito1 , M Yano1 , M Fukunaga1 , S Shirai1 , K Ando1 , 1Kokura Memorial Hospital - Kokura - Japan ,

Citation:

Background: Beta blocker (BB) is one of the most important drugs for heart failure (HF). The effect of BB is related to decrease in heart rate (HR). However, among HF patient with atrial fibrillation (AF), the relationship between BB and decrease in HR is unknown. Method and result: We enrolled consecutive 631 patients were admitted to our hospital for acute decompensated HF in 2015. 150 patients with AF both on admission and discharge was selected. 62 (41.3%) of whom received up-titration of BB in hospitalization. 127 (84.6%) of whom decreased HR on discharge comparing with on admission. The incidence of all cause death and HF re-hospitalization was not significant different between up-titration of BB group and without up-titration group (48.3% vs. 56.8%, P=0.71). The incidence of all cause death and HF re-hospitalization was significant lower in decrease in HR group than in without decrease in HR group (50.3% vs. 69.5%, P?0.01). We analyzed up-titration of BB group and without up-titration group, respectively. The incidence of all cause death and HF re-hospitalization in up-titration of BB group was significant lower in decrease in HR group than in without decrease in HR group (45.6% vs. 80.0%, P=0.03). And similar result was obtained from without up-titration of BB group (54.2% vs. 66.6%, P=0.02). Conclusion: Decrease in HR may have a better prognosis than up-titration of beta blocker for acute decompensated HF with AF.



Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are